Literature DB >> 4570671

Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris.

B Livesley, P F Catley, R C Campbell, S Oram.   

Abstract

In the treatment of angina pectoris a double-blind evaluation of verapamil (Cordilox) at two dose levels-namely, 80 mg thrice daily and 120 mg thrice daily-propranolol (Inderal) 100 mg thrice daily, and isosorbide dinitrate (Vascardin) 20 mg thrice daily has been made against a placebo. The assessment was based on relief from daily attacks of angina on effort and the response to a whole-body exercise test. We can find no statistically significant difference between the effects of verapamil (120 mg three times a day) and propranolol (100 mg three times a day) in the treatment of angina of effort. Both of these preparations are more effective than a placebo both in the reduction of daily attacks (P < 0.01) and in the prolongation of exercise test (P < 0.05). Isosorbide dinitrate (20 mg three times a day) appears to be no more effective than a placebo in the treatment of angina on effort, but 14 out of 32 patients experienced headache of such severity that even when the dose was reduced to 10 mg thrice daily this drug therapy had to be withdrawn. Both propranolol (100 mg three times a day) and verapamil (120 mg three times a day) had a significant lowering effect on the diastolic blood pressure as measured with the patient standing (P < 0.01).

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4570671      PMCID: PMC1588308          DOI: 10.1136/bmj.1.5850.375

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  20 in total

1.  The Master two-step test.

Authors:  A M Master
Journal:  Am Heart J       Date:  1968-06       Impact factor: 4.749

2.  [Effect of beta-receptor blocking agents and related substances on the excitation, contraction and energy metabolism of myocardium fibers].

Authors:  A Fleckenstein; H J Döring; H Kammermeier
Journal:  Klin Wochenschr       Date:  1968-04-01

3.  Verapamil in angina: a double-blind trial.

Authors:  D N Phear
Journal:  Br Med J       Date:  1968-06-22

4.  The effect of propranolol on exercise-induced ischemic S-T segment depression.

Authors:  R E Gianelly; B L Treister; D C Harrison
Journal:  Am J Cardiol       Date:  1969-08       Impact factor: 2.778

5.  Haemodynamic comparisons of atrial pacing and exercise in patients with angina pectoris.

Authors:  R Balcon; J Hoy; W Malloy; E Sowton
Journal:  Br Heart J       Date:  1969-03

6.  Telemetered heart rate response to selected competitive swimming events.

Authors:  J R Magel; W D McArdle; R M Glaser
Journal:  J Appl Physiol       Date:  1969-06       Impact factor: 3.531

7.  The electrocardiogram during exercise. Its value in the diagnosis of angina pectoris.

Authors:  S Bellet; O F Muller
Journal:  Circulation       Date:  1965-09       Impact factor: 29.690

8.  Confirmatory physical findings in angina pectoris.

Authors:  T Banks; G I Shugoll
Journal:  JAMA       Date:  1967-06-19       Impact factor: 56.272

9.  Cardiovascular actions of iproveratril.

Authors:  G Ross; C R Jorgensen
Journal:  J Pharmacol Exp Ther       Date:  1967-12       Impact factor: 4.030

10.  Clinical evaluation of verapamil in angina pectoris.

Authors:  G Sandler; G A Clayton; S G Thornicroft
Journal:  Br Med J       Date:  1968-07-27
View more
  34 in total

1.  Calcium antagonists: A new class of therapeutic agents.

Authors:  Antonius Gunawan; Ali Massumi; Robert J. Hall
Journal:  Cardiovasc Dis       Date:  1981-09

2.  Reassessment of failed beta-blocker treatment in angina pectoris by peak-exercise heart rate measurements.

Authors:  G Jackson; L Atkinson; S Oram
Journal:  Br Med J       Date:  1975-09-13

3.  Verapamil in ischaemic heart disease--quantitative assessment by serial multistage treadmill exercise.

Authors:  V Balasubramanian; P K Khanna; G R Naryanan; R S Hoon
Journal:  Postgrad Med J       Date:  1976-03       Impact factor: 2.401

4.  The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.

Authors:  J C McCourty; J H Silas; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

Review 5.  Calcium antagonists and their mode of action: an historical overview.

Authors:  W G Nayler; J S Dillon
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

6.  Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris.

Authors:  M Picca; F Azzollini; A Cereda; G Pelosi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

8.  Double-blind comparison of tolamolol, propranolol, practolol, and placebo in the treatment of angina pectoris.

Authors:  G Jackson; L Atkinson; S Oram
Journal:  Br Med J       Date:  1975-03-29

9.  Assessment of 'once daily' verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording.

Authors:  M Caruana; M Heber; G Brigden; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 10.  Verapamil: a review of its pharmacological properties and therapeutic use.

Authors:  B N Singh; G Ellrodt; C T Peter
Journal:  Drugs       Date:  1978-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.